News and Trends 25 Sep 2019 German Biotech Will Develop Carbohydrate-Targeting Cancer Treatments …by the Germany-based Boehringer Ingelheim Venture Fund and the French VC firm Kurma Partners. Tacalyx will use the money to generate a lead candidate antibody for the treatment of solid… September 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Jul 2023 Six companies driving Chennai’s biotech scene …modified peptides of large quantities. It also conducts epigenomic profiling which entails chromatin, RNA sequencing and DNA methylation analysis. The Chennai-based biotech company’s antibody development includes production of antibody fragments… July 28, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2020 Two UK Startups Raise Seed Funding to Revolutionize Cancer Treatment …is developing engineered antibodies called antibody-drug conjugates, which are designed to recognize cancer cells and release their chemotherapy drug payload in a targeted manner. This idea has been explored by… July 17, 2020 - 3 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
More News! 12 Nov 2018 This UK Biotech Wants to Make Antibodies Easy to Swallow Say goodbye to painful antibody injections. The UK biotech Intract Pharma has received a €1.6M grant to advance oral immunotherapy based on approved antibodies, causing less discomfort for patients. The… November 12, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 9 May 2024 BTK inhibitors: can these drugs tackle cancer and autoimmunity? …soon, rilzabrutinib could give competition to Swiss multinationals Novartis and Roche’s monoclonal antibody Xolair, which is also given to patients with CSU. Moreover, the readout of the phase 2 asthma… May 9, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2021 HIV Drug Approvals Lift Hopes Amid Missed UN Targets …project developing these antibody drugs — known as the Antibody Mediated Prevention (AMP) studies — found no strong evidence that the drugs could prevent HIV overall. Other biotechs are exploring… February 4, 2021 - 6 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2023 Project NextGen: The U.S. government’s $5 billion initiative to stay one step ahead of COVID-19 …for a new monoclonal antibody, and $100 million to explore novel vaccine and therapeutic technologies that will help to streamline the manufacturing process. To be more specific, the $1 billion… October 11, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Interview 8 Jan 2018 Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease …Both Eli Lilly and Merck suffered late-stage efficacy failures, and Merck’s candidate presented some serious side effects, as seems to be the case for drugs inhibiting β-secretase. Most recently, Axovant’s… January 8, 2018 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Elektrofi raises $40M to develop drug formulation and delivery pipeline …antibody treatments for COVID-19 and pandemic preparation. Elektrofi said it aims to provide an alternative to current delivery methods for antibody treatments, which require intravenous administration in a healthcare setting…. June 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech …Germany, licensed four candidates from its T Cell Receptor platform to Bluebird Bio in the US for up to €1B if all milestones are met. Close to that amount, Roche… December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2021 The Top European Biotech Investment Rounds in October …in September, there was only one modest IPO in October. The French firm Acticor Biotech raised €15.5M when listing on Euronext Growth Paris to fund the development of its antibody… November 2, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Agomab bags $114 million in thriving regenerative medicine sector …candidate also blocks ALK-5, but in this case, it’s designed to be inhaled for the treatment of the condition idiopathic pulmonary fibrosis. Meanwhile, Agomab is developing two antibody drugs at… July 14, 2022 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email